Recent Changes in Drug Abuse Scenario: The New/Novel Psychoactive Substances (NPS) Phenomenon by Schifano, Fabrizio et al.
Recent Changes in Drug Abuse Scenario: The New/Novel Psychoactive 
Substances (NPS) Phenomenon  
Fabrizio Schifano, MD, FRCPsych 
Over the last decade, the emergence of a vast range of new/novel/emerging 
psychoactive substances (NPS) has progressively changed the drug market 
scenario, which has shifted from a ‘street’ to a ‘virtual’/online one.  
Several definitions of NPS are in use, with the term ‘new’ not necessarily 
referring to new inventions but to substances that have recently been made 
available, possibly including a failed pharmaceutical or an old patent which has 
been ‘rediscovered’ as a ‘recreational’ molecule. Conversely, the term ‘novel’ can 
refer to something newly created; an old drug that has come back into fashion;  
or a known NPS molecule being used in an innovative or unusual way, hence 
presenting with a ‘novelty’ appeal (Corkery et al, 2018). Although misleading, 
the terms ‘legal highs’ or ’research chemicals’ have been alternatively used to 
describe these molecules. NPS include synthetic cannabinoids, cathinone 
derivatives, psychedelic phenethylamines, novel stimulants, synthetic opioids, 
tryptamine derivatives, phencyclidine-like dissociatives, piperazines, GABA-A/B 
receptor agonists, a range of prescribed medications, psychoactive plants/herbs, 
and a large series of image- and performance-enhancing drugs (IPED) (Schifano 
et al, 2015). Overall, users are typically attracted by NPS due to curiosity and 
diffusion of social media users’ experiences; easy availability/affordability from 
online drug shops; legality; intense psychoactive effects and likely lack of 
detection in routine drug screenings (Schifano et al, 2015).  
 
Between 2004 and 2017, some 700-800 NPS were reported by the related 
European and international drug agencies (UNODC, 2018; EMCDDA, 2018), with 
most molecules identified being synthetic cannabinoids, synthetic cathinones, 
phenethylamine derivatives, and synthetic opioids. However, one could argue 
that the NPS scenario is much larger than that designed by those molecules 
which have been seized/formally identified by EU/international agencies. Since 
the online NPS scenario typically predicts the real life NPS scenario (Schifano et 
al, 2015), identifying what is being discussed online by the web-based NPS 
enthusiasts ‘e-psychonauts’ (Orsolini et al, 2015) may well be of interest.  
Consistent with this, a crawling/navigating software (i.e. the ‘NPS.Finder®’) was 
recently designed by our group. In November 2017, it has started to 
automatically scan, on a 24/7 basis, a vast range of psychonaut web fora for 
new/novel/emerging NPS. After a year of operation, it has been possible to 
estimate that the online/psychonaut web fora NPS scenario may include some 
4,000 different molecules.  Most popular NPS mentioned in the psychonauts’ fora 
included: synthetic cannabimimetics; synthetic opioids; phenethylamines; 
designer benzodiazepines; and prescribed drugs.  
The issue of NPS use, and especially so for synthetic cannabinoids and novel 
psychedelics, has been associated with a range of medical untoward 
consequences, including vomiting; seizures; cardiovascular complications; and 
kidney failure (Schifano et al, 2017). Conversely, main focus of this special issue 
is on the major psychopathological consequences of NPS use. Indeed, due to 
their complex pharmacodynamics, there are increasing levels of concern about 
the onset of acute/chronic psychopathological issues associated with NPS intake.  
The occurrence of psychosis has been related to: a) increased central dopamine 
levels, typically described with novel psychedelic phenethylamines, novel 
stimulants and synthetic cathinones; b) significant cannabinoid CB1 receptor 
activation, achieved with high potency synthetic cannabimimetics; c) 5-HT2A 
receptor activation, reported with latest generation phenethylamines, tryptamine 
derivatives and hallucinogenic plants; d) antagonist activity at n-methyl-D-
aspartate/NMDA receptors, described with ketamine, methoxetamine/MXE, and 
their latest derivatives; and e) k-opioid receptor activation, typically associated 
with both Salvia divinorum and Mitragyna speciosa/’Kratom’ intake.  
 
Whilst considering the above, this Special Issue of Brain Sciences aims at 
providing an overview of a range of NPS-related issues. More precisely, Sahai et 
al present some original preclinical data relating in silico and in vitro assessment 
of psychoactive properties of a few dissociative diarylethylamines. Miolo et al 
focussed on specific analytical chemistry issues relating to amphetamine-type 
stimulants and ketamine, whilst Parrott argued about existing similarities 
between well-known recreational drugs and NPS in terms of mood 
fluctuations/psychobiological instability issues. Conversely, Cohen and Weinstein 
presented original cognitive psychopharmacology data relating to the use of 
organic and synthetic cannabinoids. From the clinical point of view, Bonaccorso 
et al presented a case series of synthetic cannabinoid users presenting to acute 
psychiatric services with psychosis; Frisoni et al commented on the medical 
consequences of novel opioids’ intake; Martinotti et al provided a thorough 
overview of the hallucinogen-persisting perceptual disorder, an issue of clear 
interest for NPS users; Schifano et al commented on the misuse/abuse of 
prescribed medicines (e.g. benzodiazepine derivatives; methylphenidate look-
alikes; and fentanyl analogues) in the NPS scenario context;  and, finally, Gittins 
et al provided empirical data relating the NPS use in clients seeking treatment in 
the UK. Both Wadsworth et al and Miliano et al commented extensively on the 
role of the open/deep web in shaping and promoting changes in NPS scenario. 
Finally, both Metastasio et al and Catalani et al presented original data shedding 
further light on the expanding phenomenon of IPED misuse/abuse.   
 
In parallel with constant changes in basic structures from which emerging 
molecules can be derived/designed/synthesized, the NPS market will continue to 
expand. This will pose a challenge, since NPS-related toxidromes are, per se, 
complex and unpredictable, and clinicians should aim at being better educated in 
recognizing NPS-related toxicity issues. Drug control policies should be improved 
worldwide, and the list of NPS should be constantly updated with improvement in 
analytical chemistry detection methods. Given the implication on mental health, 
psychiatric services should adapt to the new drug scenarios whilst drafting new 
treatment strategies.  
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